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Abstract
Metastatic dissemination of primary tumors is responsible for 90% of colorectal cancer (CRC) deaths. The pres-
ence of positive lymph nodes, which separates stage I/II from stage III CRC, is a particularly key factor in patient
management. Here, we describe results of a quantitative proteomic survey to identify molecular correlates of node
status. Laser capture microdissection and two-dimensional difference gel electrophoresis were used to establish
expression profiles for 980 discrete protein features in 24 human CRC specimens. Protein abundances were deter-
mined with a median technical coefficient of variation of 10%, which provided an ability to detect small differences
between cancer subtypes. Transgelin, a 23-kDa actin-binding protein, emerged as a top-ranked candidate biomarker
of node status. The area under the receiver operating characteristic curve for transgelin in predicting node status was
0.868 (P= .002). Significantly increased frequency of moderate- and high-level transgelin expression in node-positive
CRC was also seen using semiquantitative immunohistochemistry to analyze 94 independent CRC specimens on
tissue microarrays (P = .036). Follow-up studies in CRC cell lines demonstrated roles for transgelin in promoting
invasion, survival, and resistance to anoikis. Transgelin localizes to the nucleus of CRC cells, and its sequence and
properties suggest that it may participate in regulation of the transcriptional program associated with the epithelial-
to-mesenchymal transition.
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Introduction
Colorectal cancer (CRC) is the third leading cause of cancer death in
both men and women in the United States [1]. Metastatic dissemina-
tion of primary tumors is responsible for 90% of all CRC deaths [2].
Molecular tests are not yet widely used in establishing prognosis, and
the tumor node metastasis staging system remains the primary tool.
Detection of positive lymph nodes separates stage I/II from stage III
CRC and is often a key factor in determining patient management.
Lymph node status can only be ascertained after surgery and is strongly
influenced by the number of nodes examined [3], suggesting that pa-
tients might easily be understaged by this method.
Abbreviations: 2D-DIGE, two-dimensional difference gel electrophoresis; CRC, colo-
rectal cancer; CV, coefficient of variation; EMT, epithelial-to-mesenchymal transition;
LCM, laser capture microdissection; miRNA, microRNA; MS, mass spectrometry;
polyHEMA, poly-2-hydroxyethyl methacrylate; TMA, tissue microarray
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Here, we describe a patient-based quantitative proteomic study in
which the primary goal was to identify molecular correlates of lymph
node status in CRC. A secondary goal was to identify markers that dis-
tinguish cancer overall from patient-matched, histologically normal
colonic epithelium. The study used microdissected specimens from
24 CRC patients stratified by node status. Microdissection enriches
for tumor cells and excludes stroma and necrotic tissue, potentially in-
creasing the specificity of the screen.
The top-ranked biomarker of node status was transgelin, a 23-kDa
actin-binding protein. Paradoxically, there is previous evidence that
transgelin is both a tumor suppressor and a variable tumor biomarker,
depending on the tumor type, stage, and experimental model [4–12].
In the current study, elevated transgelin levels were predictive of node
status, although they did not differ significantly between normal colonic
epithelium and cancer overall.We also performed follow-up experiments
with transgelin to investigate its involvement in biologic processes that
are known to be relevant to metastatic behavior.
Transgelin, also known as smooth muscle protein 22α (SM22α), is
a 201–amino acid protein that contains a calponin homology domain.
It is an early marker of smooth muscle differentiation and is also pres-
ent in the cytoplasm of fibroblasts and some epithelial cells [13,14].
Transgelin promotes actin gelling in vitro (the name derives from
transformation-sensitive actin gel ling protein) [15] and is involved in
podosome formation in smooth muscle cells, thus predisposing the
cells toward migration and invasion [16]. It is associated with Ca2+-
independent vascular contractility [17] and is also a direct target of trans-
forming growth factor β (TGF-β)/Smad3–dependent epithelial cell
migration in idiopathic pulmonary fibrosis [18]. These findings are con-
sistent with a physiological role of transgelin in controlling cell motility.
CRC metastasis is a multihit, multistage process [19]. In addition
to greater motility, cells must be able to invade the extracellular ma-
trix, survive at low density outside the tumor microenvironment, and
develop resistance to anoikis, which is a form of apoptosis triggered
by loss of cell-matrix interaction. Another process that is frequently
associated with metastasis is the epithelial-to-mesenchymal transition
(EMT) [19,20]. EMT is a transcriptional program that occurs nor-
mally during embryonic development and is characterized by changes
in expression levels for E-cadherin, a mediator of cell-cell adhesion,
and other markers characteristic of mesenchymal and epithelial cells.
In the present study, we investigated whether experimental manipula-
tion of transgelin expression in established CRC cell lines influenced
invasion, survival, resistance to anoikis, and the EMT.
Materials and Methods
Tissue Specimens
CRC specimens paired with corresponding normal tissue were ob-
tained from the South Carolina Cancer Tissue Bank, University of South
Carolina. Twenty-four patients with CRC (12 node-negative, 12 node-
positive), who underwent surgery without presurgical chemotherapy or
radiation therapy during 2003 to 2005, were included (Table W1). The
institutional review boards of the University of South Carolina and the
Medical College of Georgia approved the study, and informed consent
was obtained from all patients. Tissues were snap frozen in liquid nitrogen
and stored at −80°C. Two independent pathologists confirmed diag-
nosis of all samples used in the study. Tissue microarrays (TMAs) used
in the confirmatory studies represented 94 cases of eligible CRC speci-
mens (48 node-negative, 46 node-positive) and were purchased from
US Biomax (Rockville, MD) and ISU Abxis (formerly Petagen; Seoul,
Republic of Korea).
Laser Capture Microdissection, Two-dimensional Difference
Gel Electrophoresis, and Image Analysis
Laser capture microdissection (LCM) was performed as described
[21]. Caps with microdissected cells (2500 per sample) were trans-
ferred into 90 μl of lysis buffer, incubated at room temperature for
1 hour, sonicated, and centrifuged to remove insoluble material. For
each analytical gel, 4 μg of cell lysate was reacted with 2 nmol of Tris
(2-carboxyethyl) phosphine hydrochloride (Sigma-Aldrich, St. Louis,
MO), then with 4 nmol of CyDye DIGE Fluor, Cy5, for saturation
labeling (GE Healthcare Life Sciences, Buckinghamshire, UK). Aliquots
of cell lysate from each sample were also pooled to create an internal stan-
dard, which was labeled with CyDye DIGE Fluor, Cy3, for saturation
labeling. For analytical gels, 8 μg of protein (4 μg of Cy5-labeled sample
and 4 μg of Cy3-labeled internal standard) was loaded on a 24-cm
pH 3 to 10 nonlinear immobilized pH gradient strip and focused in
an IPGphor apparatus (GE Healthcare Life Sciences) for approxi-
mately 55,000 volt-hours. Strips were applied to a 12.5% sodium
dodecyl sulfate–polyacrylamide gel and electrophoresis was performed
at 11 mA per gel overnight at 20°C in an Ettan DALTtwelve Sepa-
ration Unit (GE Healthcare Life Sciences). For mass spectrometry
(MS), 280 μg of internal standard was reduced with 140 nmol of Tris
(2-carboxyethyl) phosphine hydrochloride and labeled with 280 nmol
of the Cy3 CyDye before isoelectric focusing and sodium dodecyl
sulfate–polyacrylamide gel electrophoresis [22].
Image Acquisition and Analysis
Images were acquired using a Typhoon Trio Imager and protein
spots were defined and matched using the DeCyder 6.5 software
package (GE Healthcare Life Sciences). Intensity data were exported,
log-transformed, and normalized as described [23]. Candidate bio-
markers were identified and ranked using the Significance Analysis
of Microarrays (version 3.0, available at http://www-stat.stanford.
edu/~tibs/SAM/).
Mass Spectrometry
Protein spots in a preparative gel were matched to a master image
of the internal standard from the analytical gels. Spots of interest
were excised, digested with trypsin, and extracted [21]. Peptides were
analyzed by matrix-assisted laser desorption/ionization–MS/MS using
the ABI 4700 Proteomics Analyzer (Applied Biosystems, Foster City,
CA) or by liquid chromatography–MS/MS using an LTQ ion trap mass
spectrometer (Thermo Scientific,Waltham,MA). Protein identities were
determined using Mascot (available at http://www.matrixscience.com;
Matrix Science, Boston, MA) or the Sequest algorithm as implemented
by the BioWorks Browser v3.2 (Thermo Scientific) and the National
Center for Biotechnology Information database. Autodigested trypsin
peaks were used as an internal mass calibration standard. Evaluation of
significance was based on the score particular to the method used, the
sequence coverage, and the consistency between experimental and pre-
dicted molecular weight and pI .
Cell Lines and Transfection
Human colon carcinoma cell lines HCT116 and SW480 were pur-
chased from the American Type Culture Collection (Manassas, VA) and
maintained according to their protocols. MicroRNA (miRNA) plas-
mids targeting TAGLN were generated using the pcDNA 6.2-GW/
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EmGFP-miR vector (Invitrogen, Carlsbad, CA; refer to Table W3
for inserted sequences). After lipofectamine-mediated transfection,
stable transfectants were selected and cultured in medium containing
5 μg/ml blasticidin (Invitrogen). A double-point mutation was intro-
duced into the full-length TAGLN complementary DNA (cDNA;
Open Biosystems, Huntsville, AL) using the QuikChange Lightning
Site-Directed Mutagenesis Kit (Stratagene, La Jolla, CA) to create a
TAGLN rescue cDNA. The rescue TAGLN sequence was transferred
into pDONR 221, then pcDNA-DEST40 (Invitrogen) by site-directed
recombination. Rescue of TAGLN expression and function was assayed
at 48 hours after lipofectamine-mediated cDNA transfection.
Immunoblot Analysis, Immunohistochemistry,
and Immunofluorescence
Immunoblot analysis was carried out using antitransgelin immuno-
globulinG (IgG) and anti-GAPDH IgG1 (Abcam,Cambridge,MA)with
ECF substrate (GE Healthcare Life Sciences) for detection. Immuno-
histochemical staining was performed using the Histostain-Plus Kit
(DAB, Broad Spectrum; Invitrogen) and assessed blindly by two in-
dependent investigators (J.R.L. and Y.L.). The staining of transgelin was
scored as the product of the staining intensity (on a scale of 0-3: negative =
0, weak = 1, moderate = 2, strong = 3) and the percentage of cells stained
(on a scale of 0-3: 0 = zero, 1 = 1%-25%, 2 = 26%-50%, 3 = 51%-100%),
resulting in scores on a scale of 0 to 9 [24]. For immunofluorescence,
cells were fixed in 4% paraformaldehyde for 15 minutes, permeabilized
with 0.1% Triton X-100 for 5 minutes, and incubated with blocking
buffer (15% goat serum, 0.2% fish skin gelatin and 0.03% NaN3 in
phosphate-buffered saline) for 30minutes at room temperature. Cells were
sequentially incubated with antitransgelin IgG and antirabbit IgG con-
jugated to Alexa Fluor 594 (Molecular Probes, Eugene, OR). Slides were
mountedusingVECTASHIELDmountingmediumwith4′,6-diamidino-
2-phenylindole (Vector Laboratories, Burlingame, CA). Images were
collected using a meta confocal microscope (LSM 510; Carl Zeiss,
Thornwood, NY).
RNA Isolation and Real-time Polymerase Chain Reaction
Extraction of total RNA was performed using Trizol (Invitrogen)
followed by reverse transcription (RT). Real-time polymerase chain
reaction (PCR) was carried out using an MJ PTC-200 Chromo4
thermocycler (Bio-Rad, Hercules, CA) with a SYBR Green PCR kit
(Qiagen, Germantown, MD). Data analysis was performed using
OpticonMonitor software (version 3.1; Bio-Rad). PCR primers are
listed in Table W4.
Transwell Invasion Assay
Cell invasion assay was performed as described [25] using the
Transwell filter (pore size, 8.0 μm; 24-well plate; Corning, Inc, Life
Sciences, Lowell, MA). Filters were coated with 1.54 mg/ml Matrigel
(BD Biosciences, Sparks, MD) according to the manufacturer’s protocol.
Cells were harvested and resuspended in serum-free medium, and 5 ×
105 cells were applied onto the upper chamber of the Transwell filter.
The bottom chamber contained 0.6 ml of medium supplemented with
10% fetal bovine serum. Cells were incubated for 40 hours. Cells that
did not migrate were removed by cotton swabbing. Cells that invaded
to the lower surface of the filter were fixed and stainedwith 0.25% crystal
violet, 3.7% formaldehyde in 80% methanol for 30 minutes at room
temperature. The stained cells were extracted with 10% acetic acid,
and the absorbance at 595 nm was measured.
Clonogenic Survival Assay
Cells were plated at 3 × 102 per T-25 flask and incubated with com-
plete growth medium for 10 days for HCT116 cells and 14 days for
SW480 cells. Colonies were fixed and stained with staining buffer
(0.25% crystal violet, 3.7% formaldehyde in 80% methanol) for
30 minutes at room temperature.
Anoikis Assay
Anoikis was induced by plating the cells on poly-2-hydroxyethyl
methacrylate (polyHEMA; Sigma-Aldrich)–coated culture dishes for
72 hours. Cells were collected by gentle pipetting and either subjected
to flow cytometry analysis or replated in regular culture dishes, with
attached cells trypsinized and counted at 24 hours.
Flow Cytometry
Cells were harvested and washed once with phosphate-buffered
saline and resuspended in Annexin-binding buffer (10 mM HEPES,
140 mM NaCl, and 2.5 mM CaCl2, pH 7.4). For each reaction, 1 ×
105 cells were incubated with 10 μg RNase (Sigma-Aldrich), 1 μl of
Annexin V conjugated to Alexa Fluor 594 (Molecular Probes), and
0.8 μg of propidium iodide (Invitrogen) for 25 minutes at room tem-
perature. Flow cytometry analysis was carried out using a FACSCalibur
flow cytometer (BD Biosciences) with CellQuest software.
Statistical Analysis
Values are presented as mean ± SD. Comparisons of the means
between indicated groups were carried out using Student’s t test.
Comparisons with clinical and pathologic variables (sex, ethnicity,
histologic grade, tumor subsite, and T stage) were made using exact
tests for RxC contingency tables. TMA data were analyzed using
nonparametric Wilcoxon rank sums test [26]. A level of P < .05 was
considered significant.
Results
Proteomic Profiling of CRC and Matched Normal Epithelium
We collected CRC samples from 12 node-positive and 12 node-
negative patients (Table W1). Each CRC sample was paired with a
sample of uninvolved colonic epithelium obtained from the same
patient at the time of resection. Proteomic analysis was performed
by LCM of frozen histologic sections, followed by two-dimensional
difference gel electrophoresis (2D-DIGE) with an internal standard
design [21]. We performed a pilot study to evaluate the technical varia-
tion based on repeated LCM sampling of the same specimens. The
median coefficient of variation (CV) was 9.4% for CRC and 10.1%
for normal colonic epithelium. An improvement more than the 23%
CVs in a previous report from our laboratory probably reflects both
differences in the tissue type and the use of a microdissected rather than
bulk-dissected internal standard [22]. Assuming a total CV of 50%
(dominated by biologic variation because technical variation is only
approximately 10%), the group sizes used in the current study provided
at least 80% power to identify features with a two-fold change between
experimental groups using a two-sided α of 0.05 [22,27].
LCM and 2D-DIGE were performed on all 48 samples, and rela-
tive abundance values were derived for 980 protein spots that were
matched with high confidence across more than 90% of the gels. Sig-
nificance analysis of microarrays was used to evaluate each intergroup
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difference and to produce a list of spots, rank-ordered by difference
score (D, calculated based on the average difference between groups di-
vided by the sum of the spot-specific scatter [variance] and a measure of
scatter [variance] common to all proteins [28].) Applying a liberal 10%
false discovery rate cutoff, there were 16 spots that differentiated node-
positive from node-negative CRC and 424 spots that differentiated
CRC from patient-matched normal colonic epithelium (Figure 1A).
Interestingly, there was no more overlap between these sets than would
be predicted by chance. That is, most features that distinguished one
group of CRC from another were not useful for differentiating CRC
from normal and vice versa.
Identification of Proteins by MS
Six protein spots from the node-positive versus node-negative CRC
comparison were identified molecularly by MS. Three were metabolic
enzymes, and three were isoforms of the actin-binding protein, trans-
gelin (Table W2). On average, the change in transgelin expression
levels exceeded two-fold (Figure 1, B and C ), which was the cutoff
level for useful biomarkers that we had assumed in our power calcu-
lation. Perhaps more importantly, the area under the receiver operating
characteristic curve for a test of node status based on transgelin was
0.868 (P = .002; Figure 1D), which is considered excellent for a single
marker. Transgelin was selected for further characterization because of
its statistical ranking, ability to distinguish between groups, and pre-
vious work suggesting a role in control of cell motility [15–18].
We also identified 56 protein spots that differed in CRC versus
patient-matched colonic mucosa (Table W2). Although several seem
to be novel in the context of CRC, we have not yet investigated them
further (see Discussion).
Transgelin Expression Patterns on TMAs
We further investigated the correlation between transgelin expression
and node status in a larger, independent patient cohort by immuno-
histochemical staining of commercial TMAs. TMAs from two sources
were analyzed, representing 94 eligible cases from different geographic
regions. Representative patterns of transgelin staining are shown in
Figure 2. Staining was evident in the cytoplasm and in some cell nuclei.
Two independent investigators scored the TMAs blindly, using a 0 to
9 scale representing a combination of staining intensity and fraction of
cells stained (see Materials and Methods [24]). Increased frequency of
moderate- and high-level transgelin expression in node-positive CRC
was seen in this cohort. The distribution of scores for the node-negative
and node-positive groups was significantly different, based on aWilcoxon
rank sum test (P = .036; Table 1).
Figure 1. Proteomic profiling of CRCs stratified by node status. (A) Relationship between biomarkers identified in different comparisons.
(B) Differential expression of transgelin. Top: representative two-dimensional gel images; bottom: three-dimensional representation.
Arrowheads indicate transgelin. (C) The standardized log-transformed abundance of transgelin in node-negative and node-positive
CRC. (D) Receiver operating characteristic (ROC) curve for transgelin in prediction of node status.
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One limitation of TMAs is that each sample represents only a very
small region of the tumor (1.0- to 1.5-mm tissue core). Because of
this, a clonal subpopulation of cells that express a metastatic marker
might easily be missed, resulting in a type II error (see Discussion).
Nevertheless, the statistically significant association between trans-
gelin and node status supports the findings from quantitative pro-
teomic analysis.
Establishment of a Cell Culture Model
To investigate the potential mechanisms by which transgelin might
promote metastasis in CRC, it was desirable to establish an in vitro cell
culture model. We screened a number of CRC cell lines for transgelin
expression and selected HCT116 and SW480 for studies based on their
moderate levels of endogenous transgelin expression and the ease with
which expression of the transgelin gene (gene symbol: TAGLN ) could
be manipulated genetically.
We tested four different miRNA sequences for their ability to silence
transgelin in HCT116 cells (Figure 3A) and used the most effective
of these, TAGLN miRNA-4, to establish stably transfected popula-
tions. These populations (HCT116TAGLN-KD, SW480TAGLN-KD) and
the matched control miRNA-transfected populations (HCT116CTRL,
SW480CTRL) were characterized for transgelin protein expression by
immunoblot analysis (Figure 3B), for TAGLN mRNA by real-time
RT-PCR (Figure 3C ), and immunofluorescence staining with anti-
transgelin antibody (Figure 3D). We observed a greater than 80% de-
crease in expression in all three assays. Expression of the closely related
TAGLN3 mRNA was not significantly altered, confirming the specific-
ity of the TAGLN miRNA-4 (Figure 3C). To exclude more rigorously
off-target effects in subsequent experiments, we also created a TAGLN
rescue plasmid that expressed a TAGLN miRNA-4–resistant cDNA
(Figure 3E). Transient transfection with this cDNA restored transgelin
expression in the HCT116TAGLN-KD population (Figure 3F).
Effects of Transgelin on Cell Invasion, Survival, and Anoikis
To evaluate the effect of altered transgelin expression level on biologic
processes that are relevant to metastasis, we performed in vitro assays for
invasion, survival at low density, and anoikis.
Invasion was measured using a Transwell assay. Cells were seeded in
serum-free medium in an upper chamber, which is separated by a
Matrigel-coated filter from a lower chamber that contains medium with
10% fetal bovine serum as a chemoattractant. Results were measured
Figure 2. Illustrations of hematoxylin and eosin staining and immunohistochemistry of antitransgelin on CRC TMAs.
Table 1. Summary of Transgelin Expression on Tissue Microarrays.
Staining (Score) Node-Negative CRC (n) Node-Positive CRC (n) Total (n)
None (0) 30 (62.5%) 20 (43.5%) 50
Low (1–3) 12 (25%) 12 (26.1%) 24
Moderate (4–6) 4 (8.3%) 11 (23.9%) 15
High (7–9) 2 (4.2%) 3 (6.5%) 5
Total (n) 48 46 94
P .036
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based on staining of cells that invaded the Matrigel, migrated through
pores in the filter, and reached the lower surface. Knockdown of trans-
gelin reduced invasion by more than 50% inHCT116 cells and by 27%
in SW480 cells (P < .01; Figure 4A). Transient transfection withTAGLN
rescue plasmid, but not control plasmid, significantly restored invasion
capability to both HCT116 and SW480 TAGLN knockdown cells (Fig-
ure 4A). On the basis of the successful rescue by cDNA transfection, it is
unlikely that results are attributable to off-target effects of the miRNA.
We evaluated clonogenic survival by plating cells at low density and
scoring for colony formation after 10 to 14 days. Knockdown of trans-
gelin reduced the clonogenic survival of HCT116 cells by approximately
55% and SW480 cell by approximately 40% (P < .01; Figure 4B).
Resistance to anoikis (apoptosis induced by loss of cell-matrix
contact) was investigated by plating control and knockdown cells on
polyHEMA-coated dishes. After 72 hours, cells were characterized by
flow cytometry using Annexin V and propidium iodide stains (Fig-
ure 4C ). The total fraction of apoptotic cells in the TAGLN knock-
down groups, based on Annexin V–positive staining, increased by
1.4- to 1.8-fold, relative to the corresponding control cells (P < .01).
The percentage of viable cells in the same population was measured
independently by replating on regular dishes, incubating for 24 hours,
removing the unattached cells, and counting the remainder. Knock-
down of transgelin reduced the percentage of viable cells to 60% to
70% of control values (P < .01; Figure 4C ). Together, these results
strongly implicate transgelin in resistance to anoikis.
Effects of Transgelin Expression on Epithelial and
Mesenchymal Markers
Transgelin is normally expressed in mesenchymal cells, and its
appearance in tumor cells of epithelial origin is consistent with the
engagement of the EMT, by which tumor cells acquire a more aggres-
sive phenotype. Transgelin is localized primarily in the nucleus of CRC
cells (Figure 3D) and an 85% similar homolog, transgelin 3, is a tran-
scription factor that controls expression of the gonadotropin gene [29].
We hypothesized that transgelinmight also be a transcriptional regulator.
During the EMT, the cell intermediate filament system switches
from a keratin-rich network that connects to adherens junctions and
hemidesmosomes to a vimentin-rich network that connects to focal
adhesions [30]. Typical elements of the EMT include loss of expression
of proteins associated with adherens junctions (such as cadherins and
catenins) and tight junctions (such as occludin) and an increase in
expression of mesenchymal intermediate filament protein, vimentin,
Figure 3. MicroRNA-mediated knockdown and rescue of TAGLN in CRC cells. (A) Immunoblot analysis of HCT116 cells after transient
transfection of control miRNA plasmid and four different TAGLN miRNA plasmids. (B) Immunoblot analysis of HCT116 and SW480 cells
with stable expression of control miRNA or TAGLN miRNA-4. (C) Real-time PCR analysis of TAGLN and TAGLN3 mRNA expression in
HCT116 and SW480 cells with stable expression of control miRNA (HCT116CTRL, SW480CTRL) and TAGLN miRNA-4 (HCT116TAGLN-KD,
SW480TAGLN-KD). Gene expression was normalized to GAPDH. Data are expressed as mean ± SD from three independent experiments;
**P < .01. (D) Fluorescence microscopy of HCT116 and SW480 stably transfected cells (original magnification, ×63; white bar, 20 μm).
Panels show transgelin immunostaining, EmGFP transfection marker, 4′,6-diamidino-2-phenylindole DNA staining, and a merged image as
indicated. (E) TAGLNmiRNA target and rescue sequences. (F) Immunoblot analysis of HCT116TAGLN-KD cells after transient transfection with
empty vector or TAGLN rescue plasmid.
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Figure 4. Effects of TAGLN silencing on HCT116 and SW480 cell invasion, survival, and anoikis. (A) Invasion assay. Representative images
of Transwell filters indicating HCT116CTRL and HCT116TAGLN-KD invasion are shown. Bar graphs show comparison of invasion capacities of
HCT116 and SW480 stably transfected cells (left) and HCT116TAGLN-KD and SW480TAGLN-KD cells after transient transfection with 1 μg of
empty vector or TAGLN rescue plasmid (right). (B) Clonogenic survival assay. Representative images of HCT116CTRL and HCT116TAGLN-KD
cells. Graph shows the number of colonies formed 10 and 14 days after plating HCT116 and SW480 stably transfected cells, respectively.
(C) The anoikis-induced apoptosis was measured by Annexin V and propidium iodide staining and flow cytometry analysis at 72 hours after
plating HCT116 and SW480 stably transfected cells on polyHEMA-coated culture dishes. Anoikis was also assessed by counting the viable
cells at 24 hours after replating the anoikis-induced cells on regular culture dishes. Values for control cells were considered 100%, any
differences are expressed relative to this value. Data are expressed as mean ± SD from three independent experiments; **P < .01.
Figure 5. EMT marker genes regulated by TAGLN. The mRNA levels of the epithelial marker genes occludin (OCCL) and mesenchymal
marker genes vimentin (VIM) and fibronectin 1 (FN1) in HCT116CTRL and HCT116TAGLN-KD cells (A) and in SW480CTRL and SW480TAGLN-KD
cells (B). Gene expression was measured by real-time RT-PCR and normalized to GAPDH. Data are expressed as mean ± SD from three
independent experiments; **P < .01, *P < .05.
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and the mesenchymal adhesion protein, fibronectin [18,30–32]. In
HCT116 cells, knockdown of transgelin was associated with the up-
regulation of mRNA encoding occludin and with the down-regulation
of mRNA encoding fibronectin-1 and the mesenchymal intermediate
filament protein vimentin (Figure 5A). The mRNA levels for two other
epithelial markers, E-cadherin and β-catenin, were unaffected (data not
shown). In SW480 cells, transgelin knockdown had less effect. Of the
mRNA investigated, only fibronectin-1 was significantly influenced (Fig-
ure 5B). The finding that alteration of transgelin affects mRNA levels for
some, but not all, EMT-associated genes supports the hypothesis that
transgelin is a promoter-selective regulator of transcription. An ability
to regulate transcription of other genes provides a mechanism by which
transgelin might broadly influence processes relevant to metastasis.
Discussion
We performed a patient-based proteomic study to seek proteins that
correlated with lymph node status. We obtained quantitative expres-
sion data for 980 protein spots. Of these, transgelin had three qualities
that made it particularly interesting for follow-up: it had the highest
statistical ranking as a predictor of node status, it was novel in the con-
text of CRC metastasis, and there was a variety of previous evidence in
other systems that linked it to cell motility. To explore possible mecha-
nisms by which transgelin could influence metastatic behavior, we
created two pairs of isogenic CRC cell lines that differed in transgelin
levels. In both instances, attenuation of expression resulted in loss of
characteristics believed to be important for metastasis, including inva-
sion, survival at low density, and resistance to anoikis.
In theory, identification of metastatic biomarkers in primary tumors
should be problematic because cells that express such markers may be
too rare to influence a population-averaged expression profile [19]. In
practice, however, biomarkers that correlate with metastatic risk have
been identified in several other cancers, including breast and prostate
cancer. Metastasis is a complex process, and it may be that stepwise
acquisition of metastatic potential leads to expansion of clones express-
ing genes that are necessary, but perhaps not sufficient, for forming
metastasis [19]. We suggest that TAGLN may be among these genes.
CRC has been shown to arise initially through two major genetic
pathways: one is chromosomal instability, and the other is micro-
satellite instability [33–35]. Other routes of carcinogenesis include the
TGF-β/SMAD signaling pathway, the serrated pathway, and the epi-
genetic pathway (reviewed in Takayama et al. [36]). However, the
mechanisms that are responsible for metastasis seem to be much more
complex [37,38]. EMT and tumor-microenvironment interaction have
begun to receive significant attention [20]. EMT is mediated by the net-
work signaling of TGF-β, Wnt, mitogen-activated protein kinase, phos-
phatidylinositol 3-kinase/Akt, Snail, Slug, SMAD-interacting protein 1,
and E2A proteins [20]. Influences of tumor microenvironment include
degradation of extracellular matrix by matrix metalloproteinases, changes
in adhesion molecules (integrins and cadherins), increased angiogenesis
mediated by vascular endothelial growth factor, and changes in cell
survival and differentiation mediated by TRAIL receptor, CXCR4 and
Drg-1. [36,39]. The hepatocyte growth factor/MET pathway may also
be important in EMT [40], CRC cell invasiveness, and metastasis [41–
45]. Recently, themetastasis-associated in colon cancer-1 gene (MACC1)
has been reported to be an independent prognostic indicator of CRC
metastasis. MACC1 regulates the expression of MET, the hepatocyte
growth factor receptor [38].
Our initial quantitative proteomic analysis suggested that transgelin
expression might be able to serve as a surrogate marker of node status.
This would require an analytical method with higher throughput than
the LCM/2D-DIGE. However, the method would need to preserve
the advantages of LCM/2D-DIGE, including 1) accurate quantifica-
tion, 2) an ability to sample a reasonable fraction of the tumor, and
3) an ability to exclude stroma. Because transgelin is expressed normally
in smooth muscle and fibroblasts, inclusion of stroma might easily
confound the analysis. We used immunostaining of TMAs as a higher
throughput method to evaluate the correlation between transgelin and
node status (Figure 2). This method allowed exclusion of stroma but
was only semiquantitative and sampled a much smaller region of each
tumor than the LCM/2D-DIGE. As might be expected, the results,
although showing a significant difference between groups, had much
lower sensitivity and specificity. In particular, there were a high per-
centage of transgelin-negative samples in both groups. A number of
new methods of proteomic analysis are in development (reviewed in
Lin et al. [46]). Imaging MS is a particularly promising method
[47,48], and it is compatible with direct detection of a small protein,
such as transgelin, within tissue sections. Analysis of tissue sections
using imaging MS would be a logical next step in evaluating the clinical
usefulness of transgelin as a biomarker.
An actin-binding protein, such as transgelin, has the potential to
alter cell motility through direct interaction with the actin cytoskeleton.
However, the predominantly nuclear localization in cultured CRC cells
(Figure 3D) and the influence on the expression levels of several EMT-
associated genes (Figure 5) led us to explore an alternative hypothesis,
that is, transgelin is a transcriptional regulator. Recent evidence shows
that actin plays an important role in nuclear processes, including tran-
scription, chromatin remodeling, and transcription factor regulation
[49–53]. Indeed, many of the more than 60 classes of actin-binding
proteins in human cells localize to the nucleus [54]. These nuclear
actin-binding proteins are associated with diverse processes, including
transcriptional regulation and DNA repair [55,56]. Transgelin contains
a C-terminal calponin-like module, which is required for actin bind-
ing in other proteins [57]. In addition, bioinformatic analysis using
the “DP-bind” Web server (http://lcg.rit.albany.edu/dp-bind) iden-
tified several segments of the transgelin primary sequence as having
high DNA-binding potential (data not shown). Together, these obser-
vations support a hypothesis that transgelin could be an adaptor that
mediates interaction between nuclear actin and DNA. Direct investiga-
tion of interactions between transgelin and other macromolecules in
the nucleus will be required to evaluate this possibility.
The observation that transgelin expression is elevated in node-positive
CRC raises a question of what controls transgelin expression itself.
TAGLN spans 5.4 kb on chromosome 11q23.2, with putative promoter
elements approximately 800-bp upstream of the open reading frame
[58]. These include a TGF-β control element [59], smad-binding ele-
ments, and serum response factor–binding CArG boxes [60]. Several
studies have shown that transgelin expression is under the control of
the TGF-β signaling pathway in other systems [18,58,61–64]. TGF-β
plays a paradoxical role in regulating tumor cell growth and migration.
During early tumor development, it is an inhibitor of proliferation, but
later in CRC progression, it switches to become a promoter of growth
and invasion [65,66] and is important for the EMT [67–70]. If trans-
gelin expression is under TGF-β control, it may explain why expression
is associated with tumor suppression in some studies and is a variable
tumor biomarker in the others [4–12].
Although transgelin is the only protein we have investigated in detail,
the proteomic survey did lead to other potentially interesting findings.
A few proteins identified in the cancer-versus-normal comparison in
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the current study are novel in the context of CRC and seem to have
cancer-relevant biologic functions. One of these is a component of
the IκB kinase complex, ELKS/RAB6-interacting/CAST family mem-
ber 1. Another is zinc finger protein 224, which is a transcriptional re-
pressor that interacts with a corepressor, KRAB-associated protein 1
[71], which is upregulated in metastatic breast cancer [72]. These
and other proteins that emerged in the CRC-versus-normal comparison
have yet to be investigated.
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Table W1. Demographics of the Patients Included in the Proteomic Study.
Node-Negative (n = 12) Node-Positive (n = 12) P
Age (years) 68.17 ± 11.71 62.08 ± 12.30 .670
Sex
Male 8 6 .680
Female 4 6
Ethnicity*
White 7 6 .415
African-American 3 6
Maximum diameter of the
tumor (cm)
4.75 ± 1.99 5.32 ± 1.99 .464
Histologic grade
Moderate 11 10 1.000
Poor 1 2
Primary site
Left colon 7 6 1.000
Right colon 3 4
Rectum 2 2
Primary tumor
T2 2 1 1.000
T3 10 10
T4 0 1
*The ethnicity information of two patients from the node-negative group was missing.
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Table W4. Primers for Real-time RT-PCR.
Gene Forward Primer (5′-3′) Reverse Primer (5′-3′)
TAGLN GTTCCAGACTGTTGACCTCTTT CTGCGCTTTCTTCATAAACC
TAGLN3 ATGGGAAGGGAAGGACATGGC GCTGGGCTTTCCTGTGAAACC
ECAD ATACACTCTCTTCTCTCACGCTGTG AAGAGCACCTTCCATGACAGAC
OCCL CCTGATGAATTCAAACCGAATC AGGAGAGGTCCATTTGTAGAAGTGA
CTTNB1 AAATGCTTGGTTCACCAGTGGAT CACTGCCATTTTAGCTCCTTCTTG
VIM TTCAGACAGGATGTTGACAATGC GGATTTCCTCTTCGTGGAGTTTC
FN1 CGAGAGTAAACCTGAAGCTGAAGAG GATGCAGGTACAGTCCCAGATC
GAPDH ACAGCCTCAAGATCATCAGCAAT ATGGACTGTGGTCATGAGTCCTT
Table W3. Sequences Inserted in TAGLN miRNA Plasmids.
DNA Oligos Top Strand (5′-3′)
Hmi416872 top TGCTGATCTGAAGGCCAATGACATGCGTTTTGGCCACTGACTGACGCATGTCAGGCCTTCAGAT
Hmi416872 bottom CCTGATCTGAAGGCCTGACATGCGTCAGTCAGTGGCCAAAACGCATGTCATTGGCCTTCAGATC
Hmi416873 top TGCTGAACTGATGATCTGCCGAGGTCGTTTTGGCCACTGACTGACGACCTCGGGATCATCAGTT
Hmi416873 bottom CCTGAACTGATGATCCCGAGGTCGTCAGTCAGTGGCCAAAACGACCTCGGCAGATCATCAGTTC
Hmi416874 top TGCTGTGCACTTCGCGGCTCATGCCAGTTTTGGCCACTGACTGACTGGCATGACGCGAAGTGCA
Hmi416874 bottom CCTGTGCACTTCGCGTCATGCCAGTCAGTCAGTGGCCAAAACTGGCATGAGCCGCGAAGTGCAC
Hmi416875 top TGCTGTGTGAATTCCCTCTTATGCTCGTTTTGGCCACTGACTGACGAGCATAAGGGAATTCACA
Hmi416875 bottom CCTGTGTGAATTCCCTTATGCTCGTCAGTCAGTGGCCAAAACGAGCATAAGAGGGAATTCACAC
